康惠制药: 康惠制药关于控制权拟发生变更事项通过上海证券交易所合规性审核暨控制权拟发生变更的进展公告

Core Viewpoint - The announcement details a significant change in control for Xi'an Kanghui Pharmaceutical Co., Ltd., as its controlling shareholder, Kanghui Holdings, plans to transfer 22% of its shares to Jiaxing Yuehe Zhichuang Technology Partnership, resulting in a new controlling entity and actual controllers [2][3]. Group 1: Equity Change Overview - Kanghui Holdings intends to transfer 21,973,600 shares, representing 22% of the total shares of the listed company, to Yuehe Zhichuang at a price of RMB 24.70 per share [2]. - Following the completion of this share transfer, the controlling shareholder will change to Yuehe Zhichuang, with the actual controllers being Li Hongming and Wang Xuefang [2]. Group 2: Progress of Equity Change - The equity change has passed compliance review by the Shanghai Stock Exchange [3]. - The final implementation of the share transfer is subject to the completion of share transfer registration procedures at the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, indicating some uncertainty in the final outcome [3].